Oral rifampicin in cases of cutaneous leishmaniasis with multiple lesions (a pilot study).
The multiple lesions of cutaneous leishmaniasis (CL) require an effective oral agent. We are reporting a pilot study of oral rifampicin 600 mg. bid or 20 mg/kg. body weight in cases of CL with multiple lesions. Our study shows 83.3% parasitological and clinical cure with insignificant side effects after 4 weeks of therapy. No relapse upto 6 months of completion of study was seen.
Bumb
R A
RA
Department of Skin, V.D. & Leprosy, S.P Medical College & A.G. of Hospitals, Bikaner-334 003, India. drrabumb@nda.vsnl.net.in
Mehta
R D
RD